Treatment

TYRA-300-B01 clinical trials

1 indexed studies · 0 currently recruiting

RecruitingPhase II
Phase II study of TYRA-300 in children with achondroplasia
This study looks at a new medicine called dabogratinib (TYRA-300) for children with achondroplasia. It aims to find a safe and effective dose to help bone growth in children aged 3 to 10 whose growth plates are still open.
For: Achondroplasia with open growth plates Therapeutic areas: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
United Kingdom · England · Australia